Advanced NSCLC Monotherapy Treatment

Exploratory analysis:
PD-L1 expression levels ≥50%

In the subset of patients with advanced NSCLC* with no EGFR, ALK, or ROS1 aberrations and known PD-L1 ≥50% (n=563):

Exploratory analysis of PD-L1 expression1

Change in target tumor measurement with baseline PD-L1 tumor proportion scores1

Limitations:

This is an exploratory analysis that was not powered to show a statistically significant difference among or within varying PD-L1 expression levels. Firm conclusions cannot be made based on these exploratory analyses.

Percentage change from baseline in the diameter of target tumor measurement (LOCF)

Exploratory analysis of tumor response by PD-L1 expression Exploratory analysis of tumor response by PD-L1 expression
  • Adapted with permission from Sezer et al, Lancet 2021.1
  • *Patients with locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation or who had metastatic NSCLC.1
  • LOCF=last observation carried forward.

In the subset of patients with advanced NSCLC* with no EGFR, ALK, or ROS1 aberrations and known PD-L1 ≥50% (n=563):

Exploratory analysis of PD-L1 expression1

Survival and objective response with baseline PD-L1 tumor proportion scores1

Limitations:

This is an exploratory analysis that was not powered to show a statistically significant difference between or within varying PD-L1 expression levels. Firm conclusions cannot be made based on these exploratory analyses.

PD-L1 ≥90%
LIBTAYO (n=98)
Chemotherapy (n=94)
Number of patients
Overall survival per BICR
Median, months (95% CI)
NR (17.3-NE)
15.1 (11.1-NE)
Hazard ratio (95% CI)
0.46 (0.25-0.85)
Progression-free survival per BICR
Median, months (95% CI)
15.3 (10.4-18.7)
5.9 (4.3-6.2)
Hazard ratio (95% CI)
0.28 (0.17-0.46)
Tumor response per BICR
Objective response rate, % (95% CI)
46 (36-56)
18 (11-27)
 
LIBTAYO (n=89)
Chemotherapy (n=90)
Number of patients
Overall survival per BICR
Median, months (95% CI)
22.1 (17.9-NE)
12.0 (9.6-19.2)
Hazard ratio (95% CI)
0.47 (0.27-0.80)
Progression-free survival per BICR
Median, months (95% CI)
6.2 (4.2-8.4)
4.2 (4.1-5.7)
Hazard ratio (95% CI)
0.55 (0.38-0.80)
Tumor response per BICR
Objective response rate, % (95% CI)
39 (29-50)
20 (12-30)
 
LIBTAYO (n=96)
Chemotherapy (n=96)
Number of patients
Overall survival per BICR
Median, months (95% CI)
21.9 (13.2-NE)
14.0 (9.4-19.3)
Hazard ratio (95% CI)
0.77 (0.49-1.23)
Progression-free survival per BICR
Median, months (95% CI)
4.3 (2.8-6.3)
6.2 (5.0-6.2)
Hazard ratio (95% CI)
0.79 (0.56-1.12)
Tumor response per BICR
Objective response rate, % (95% CI)
32 (23-43)
23 (15-33)
 
  • Adapted with permission from Sezer et al, Lancet 2021.1
  • *Patients with locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation or who had metastatic NSCLC.1
  • NR=not reached.

Reference: 1. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604.

Reference: 1. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604.